share_log

B of A Securities Maintains Neutral on ProKidney, Raises Price Target to $4

B of A Securities Maintains Neutral on ProKidney, Raises Price Target to $4

Bof A證券對ProKidney維持中立,將目標股價上調至4美元
Benzinga ·  05/29 17:21

B of A Securities analyst Jason Gerberry maintains ProKidney (NASDAQ:PROK) with a Neutral and raises the price target from $3 to $4.

B of A Securities分析師傑森·格伯裏維持ProKidney(納斯達克股票代碼:PROK)的中性評級,並將目標股價從3美元上調至4美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論